ASX Linkedin Twitter               

 

Clinical Trials – Phase 1 CANON

CANON Trial

Status: Study Complete

A Phase 1 Trial entitled CANON (CAVATAK in NON– muscle invasive bladder cancer) has been completed at the Surrey Cancer Research Institute, United Kingdom.  This trial investigated the intravesicular use of CAVATAK® for treatment of non-muscle invasive bladder cancer (NMIBC) .

The first stage of the CANON study evaluated CAVATAK delivered as a monotherapy via a catheter directly into the bladder. The second stage of the study examined CAVATAK given in conjunction with mitomycin C by the same route of administration, with a goal of establishing a recommended Phase 2 dosing regimen for the combination therapy.

Investigators also examined the pharmacodynamics of CAVATAK and documented any evidence of anti-tumour activity.

For further information about this trial, please visit the Clinical Trial website at ClinicalTrials.gov Identifier: NCT02316171

The trial was completed in late 2016 with evidence of anti-cancer activity and tumour targeting demonstrated. Click here for the latest news on the CANON study

Viralytics Limited
Suite 305, Level 3, 66 Hunter Street
Sydney NSW 2000 Australia
T: +61 (0)2 9988 4000 F: +61 (0)2 8068 6038

© Viralytics Limited 2017
This information does not take your circumstances into account. Read the relevant ASX releases, financial reports and prospectuses before making an investment decision. Shares in Viralytics Limited, ABN 12 010 657 351, are traded on the Australian Stock Exchange (ASX:VLA) and on the over-the-counter market (OTC: VRACY).